The Top 25 IVD Companies: Revenue Performance, Products, Strategies, Market Activities

 
   Single User - $2,500
   Site License (one location, 10 users) - $3,750
   Corporate License - $5,000



Loading...
Published Oct 5, 2017 | 225 Pages | Pub ID: KLI15498064

The Top 25 IVD Companies: Revenue Performance, Products, Strategies, Market Activities

Visit our 'In Vitro Diagnostics' curated page for all-in-one industry coverage.

From the IVD Experts: Who's Winning, Who's Growing, Who's Launching Products, Who's Buying Whom?

Clinical laboratory technology has changed dramatically in the past few years, due to the publication of the human genome project and advances in functional genomics, bioinformatics, miniaturization and microelectronics. Not five years ago it would have been almost inconceivable to see research technologies such as genome sequencing and mass spectroscopy play a pivotal role in improving lab medicine. Their influence is felt in personalized medicine, inherited diseases, pathogen detection, antibiotic resistance testing, blood banking and much more to come.

Authored by Shara Rosen, senior IVD analyst at Kalorama Information and author of The Worldwide Market for In Vitro Diagnostics Test, this report, IVD Market Top 25 Companies presents advancements in in vitro diagnostics (IVD) by the Top 25 companies in the industry and provides an overview of the most recent trends and developments.  

IVD Companies Profiled Include:

  • Abbott Diagnostics
  • Alere Inc.
  • Arkray
  • Beckman Coulter / Danaher
  • Becton Dickinson
  • Bio-Rad Laboratories
  • bioMérieux
  • Cepheid / Danaher
  • Danaher Corp. (including Radiometer A/S)
  • Grifols
  • Hologic
  • Illumina
  • Instrumentation Laboratory / Werfen
  • LabCorp, Laboratory Corporation of America
  • Luminex
  • Ortho Clinical Diagnostics
  • PerkinElmer
  • Qiagen N.V.
  • Quest Diagnostics
  • Quidel
  • Roche Diagnostics (including Ventana Medical Systems)
  • Philips
  • Siemens Healthineers
  • Sysmex Corporation
  • Thermo Fisher Scientific

Notable IVD Company Events

The Top 25 IVD Companies: Revenue Performance, Products, Strategies, Market Activities examines the major companies in the IVD industry in terms of
  • Recent Revenue History and Commentary
  • Business Overview 
  • Revenue in Selected Test Segments
  • Current and New Products
  • Competitive Activity: M&A, Partnerships and Other Moves
The top five majors continue to bring innovations to clinical diagnostics. However, of particular interest in the past year or so are the efforts made by companies such as Bio-Rad Laboratories, Illumina, and Thermo Fisher Scientific. These and other companies are translating their portfolio of research-based molecular solution to clinical tools.

In Vitro Diagnostics Market Trends

While assembling the company information found in IVD Market Top 25 Companies: Revenue Performance, Products, Competitive Activity, several trends became apparent. The report reviews these trends. . . .

Gene Editing

A review of the advancements reported by the major IVD companies included in this report shows innovations in CRISPR gene editing that is being adapted to the diagnosis of problematic diseases and the development of new therapeutics.

Liquid Biopsy

The report presents selected liquid biopsy innovations. For example, QIAGEN has been pioneering innovation in molecular testing and has recently put new muscle in the diagnosis and monitoring of cancer with non-invasive circulating tumor cell and cell free DNA (liquid biopsy). The potential of these technologies has attracted other major IVD companies to enter the market for these tests.

Microbiome

Intense research into the relationship of a person’s population of normal flora and pathogenic invaders with the etiology and progression of disease states has been developed into microbiome-based molecular testing. At this time, most testing is available from service providers and for research.

Patient Service Center Revival

In 2017, various news reports have indicated that Quest Diagnostics (Quest) and Laboratory Corporation of America (LabCorp) have become more active and have been opening more patient service centers in grocery stores and retail pharmacies.

IVD Companies Mix and Match: Menu Expansion by Partnering and Acquisitions

Human genome research is providing areas of expansion for molecular testing. Decreases in life science funding in the U.S. has encouraged companies active in this space to migrate their technologies for clinical applications. The result is the entry of companies such as Illumina, Thermo Fisher Scientific, PerkinElmer and Affymetrix (now part of Thermo Fisher Scientific) to the diagnostics market. They have made investments to become “clinical” companies. These companies join expansion activity into new market segments by companies already involved in the IVD industry. The report provides a sampling of the initiatives that selected companies have taken to expand their product portfolio, particularly in molecular testing.

Direct to Consumer Genomics

The U.S. FDA has slowly relaxed its strict stance in the area of direct to consumer genome services and a number of new offerings have been commercialized.

In Vitro Diagnostics: Looking to the East

The repercussions of recent economic instability in North America and Europe are still very obvious at this time. In an effort to maintain growth, IVD companies have begun to look to markets outside their home and traditional geographies. The major IVD companies have been active in Asia, Africa, and Latin America for some time and have increased their efforts there.

IVD Market Top 25 Companies also presents highlights of IVD industry developments as demonstrated by a selection of small and niche companies in 2016 and the first half of 2017. Small companies are also preparing for the future with the development of next generation systems, informatics to help labs manage and retrieve test data, new infectious disease diagnostics and gene-based oncology tests for targeted therapeutics.

Quantitative company data is provided in U.S. dollars for the years 2016 and the first half of 2017. No adjustments have been made to the market data for the effects of currency exchange fluctuations or inflation. Kalorama has decided to use a constant exchange rate because this provides a more accurate reflection of actual revenue growth in dollars rather than growth due to exchange rate fluctuations.
In this report,  {{key}} appears {{searchResults.reportMatchCounts[value]}} times
We were unable to search inside this report.
No results matched your search criteria.

Search for an exact word or phrase by placing the word or phrase in quotation marks ("market trend"). Search for different versions or tenses of a word by placing an asterisk at the end of the word (pharma*).

Please note that your term must be at least three characters long and numbers will be blocked by the # sign.